Drug Innovation Needs Exclusivity For Some Natural Substances, PhRMA Recommends
Executive Summary
In comments on VMS industry oversight, PhRMA recommends FDA adhere to clear regulations that determine whether substances are eligible for use as dietary ingredients. DSHEA makes clear that some dietary ingredients are not eligible for use VMS products.
You may also be interested in...
IND Firms Contend Lax NDI Notification Enforcement Threatens Their Chances
Three pharma submit similar complaints to FDA's NAC docket stating the FDA isn’t sufficiently protecting their interests by allowing use of dietary ingredients similar to the drugs they’re developing.
In NAC Docket, NAD+ Drug Firm Suggests US FDA Get Serious About Dietary Ingredient Regulations
MetroBiotech argues it and other drug developers and manufacturers are harmed as FDA allows NAD+ use in dietary supplements without requiring new dietary ingredient notifications and despite DSHEA’s preclusion clause.
US CBD Supplement Market Anxious For Lawful Use Proposal, And FDA Offers Cannabis Drug Research Guidance
Adding more cannabis-containing drugs to the three already approved in the US relies on research, but hundreds of supplements and other FDA-regulated non-drug products containing CBDs already are available under enforcement discretion by the agency.